Plain-English translation of NCT06568926 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Beta-Thalassemia research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This research study is looking at how well young patients with beta thalassemia follow their prescribed iron removal medication called deferasirox. The study wants to understand what makes it easier or harder for patients to take this medicine regularly, so doctors can help patients stick with their treatment better.
Patients with beta thalassemia need regular blood transfusions to survive, but these transfusions cause dangerous iron buildup in the body. Taking iron removal medication is critical to prevent serious organ damage, but many patients struggle to take it consistently—and researchers want to understand why.
As a participant, you would share information about how you are taking your iron removal medication—whether you take it as prescribed, what challenges you face, and what helps you remember to take it. The researchers will likely collect this information through interviews or surveys during visits to the hospital or clinic where you receive your thalassemia care.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
Egypt
Sponsor
Sohag University
Enrollment target
~200 participants
Started
July 2024
Primary completion
July 2025
Age range
2 Years – 18 Years
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marwa Ali Mousa, resident
Sohag University